Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome with Type 2 Diabetes Mellitus

  • Alecardio was a Phase III, multi-center, randomized double blind, placebo-controlled trial

  • Conducted in 720 hospitals in 26 countries throughout North America, Latin America, Europe and Asia-Pacific regions

  • The enrollment of 7,226 patients hospitalized for ACS (myocardial infarction or unstable angina) with type 2 diabetes occurred between February 2010 and May 2012

  • Treatment was planned to continue until patients were followed-up for at least 2.5 years and 950 primary end point events were positively adjudicated


Alecardio Metrics - Argentina

  • Sites Initiated: 32

  • Sites Randomized: 25

  • Patients Screened: 175

  • Patients Randomized: 156